(TSX-V:MATA),(OTC US:MTDTF),(OtherOTC:MTDTF), TORONTO, March 31, 2025 (GLOBE NEWSWIRE) — Matador Technologies Inc. (“Matador” or the “Company”) (TSXV: MATA, OTCQB: MTDTF) announces the addition of two members to its team as the Company advances toward the launch of its digital gold product on the Bitcoin network in early 2025. Antoine De Vuyst has joined Matador as […]
Dr. William Sellers is a leading cancer researcher who currently serves as a Core Institute member and Director of the cancer program at the Broad Institute and a professor of medicine at Dana-Farber Cancer Institute and Harvard Medical School He brings deep expertise and experience in cancer biology and cancer therapeutics to Atavistik Bio as
(Other OTC:BSEM),(OTC US:BSEM), POMPANO BEACH, Fla., March 31, 2025 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for two of
CHICAGO, March 31, 2025 (GLOBE NEWSWIRE) — Pando, the leading supply chain AI company, has been recognized by Gartner as a Visionary in the 2025 Magic Quadrant for Transportation Management Systems. Pando's AI Agents replace staff and software at Fortune 500 manufacturers, distributors, and retailers worldwide, automating work done by logistics teams to deliver products
(NasdaqGM:TCRX), WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the 24th Annual Needham Virtual
WATERTOWN, Mass., March 31, 2025 (GLOBE NEWSWIRE) — Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the Stifel 2025 Virtual Targeted Oncology
(LSE – AIM:AVCT), AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025 AVA6103 IND-enabling studies underway with a Phase 1 trial anticipated to begin in the first quarter of 2026 Multiple presentations at the AACR Annual Meeting highlight the promise of the pre|CISION(R) platform Transformation into a pure-play therapeutics company prioritizes
— Early adopters of Gable see incident resolution time improve by up to 70%, and development cycles for data-dependent features accelerate by 50%. — The “Shift Left” approach transforms data teams from reactive cost centers to proactive value creators, allowing organizations to build higher-quality data assets from the start. — Watch Gable's inaugural Shift Left
(NASDAQ:LPLA), SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) — LPL Financial Holdings Inc. (NASDAQ: LPLA) (together with its subsidiaries, including LPL Financial LLC, “LPL Financial” or “LPL”) today announced that it has commenced an underwritten public offering of $1.5 billion of its common stock. Morgan Stanley & Co. LLC is acting as sole active book-running
— Divesting natural gas distribution business in Mexico — Selling minority interest inSempra Infrastructure Sempra (NYSE: SRE) today announced several strategic actions to advance its ongoing commitment to simplify the company's portfolio and recycle capital in support of strong growth in its Texas and California utilities. Sempra intends to sell certain energy infrastructure assets in